Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 19372 | AA26-9 | 1312782-34-5 | >98% |  |
| AA26-9 is a potent and broad-spectrum serine hydrolase inhibitor. AA26-9-inhibited en | ||||
| 19365 | AZD-0284 | 2101291-07-8 | >98% |  |
| AZD-0284 is a potent, selective, inverse agonist of the nuclear receptor RORγ for th | ||||
| 19363 | AZ304 | 942507-42-8 | >98% |  |
| AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type B | ||||
| 19356 | AZ876 | 898800-26-5 | >98% |  |
| AZ876, also known as AZ-876, is a liver X receptor agonist. AZ876 protects against pa | ||||
| 19316 | AGN-190299 | 118292-41-4 | >98% |  |
| Tazarotene is a retinoid prodrug which is converted to its active form, the cognate c | ||||
| 19315 | AM281 | 202463-68-1 | >98% |  |
| AM281 is a synthetic cannabinoid CB1 receptor antagonist. | ||||
| 19312 | ASP9521 | 1126084-37-4 | >98% |  |
| ASP9521 is a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid d | ||||
| 192275 | AZD0364 | 2097416-76-5 | >98% |  |
| AZD0364 is an ERK1 and/or ERK2 kinase for the treatment of cancer. ERK1 and ERK2 kina | ||||
| 192212 | ATF6-activator-147 | 393121-74-9 | >98% |  |
| ATF6-activator-147 is an ATF6 simulator which acts as a prodrug that preferentially t | ||||
| 192156 | AZD1152 | 722543-31-9 | >98% |  |
| AZD1152 is a pro-drug of Barasertib-hQPA, which is a highly selective Aurora B inhibi | ||||
| 191287 | AZD3229 | 2248003-60-1 | >98% |  |
| AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal st | ||||
| 191251 | AM095 sodium | 1345614-59-6 | >98% |  |
| AM095 is a potent LPA1 receptor antagonist because it inhibited GTPγS binding to Chi | ||||
| 191212 | AZD4573 free base | 2057509-72-3 | >98% |  |
| AZD-4573 is a selective, short-acting inhibitor of the serine/threonine cyclin-depend | ||||
| 191146 | AR-9281 | 913548-29-5 | >98% |  |
| AR-9281 is a soluble epoxide hydrolase (s-EH) inhibitor potentially for the treatment | ||||
| 191112 | ARRY-797 (ARRY-371797) | 1036404-17-7 | 99% Min. | _1036404-17-7.png) |
| ARRY-797 is an oral, selective p38 mitogen-activated protein kinase inhibitor. ARRY-7 | ||||
| 19141 | Abivertinib | 1557267-42-1 | >98% |  |
| Abivertinib, also known as AC0010 and Avitinib, is a tyrosine kinase inhibitor, antin | ||||
| 1812294 | AZD7507 | 1041852-85-0 | >98% |  |
| AZD7507 is a potent and selective CSF-1R inhibitor (32 nM cell activity), AZD7507 is | ||||
| 1812281 | Auranofin | 34031-32-8 | >98% |  |
| Auranofin, also known as Ridaura and SKF-39162, is an oral chrysotherapeutic agent fo | ||||
| 181254 | AX-024 HCl | 1704801-24-0 | >98% |  |
| AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively i | ||||
| 1811303 | AG 879 | 148741-30-4 | >98% |  |
| AG-879 is a tyrphostin compound that inhibits nerve growth factor-dependent TrkA tyro | ||||
| 1811283 | Avagacestat | 1146699-66-2 | >98% |  |
| Avagacestat, also known as BMS-708163, is an oral GSI designed for selective inhibiti | ||||
| 1811265 | AS1842856 | 836620-48-5 | >98% |  |
| AS1842856 is a cell-permeable Foxo1inhibitor that blocks the transcription activity o | ||||
| 1811211 | Anlotinib HCl ( AL-3818 ) | 1360460-82-7 | ≧98.0% | _1360460-82-7.png) |
| Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) targeting c-kit, platelet-d | ||||
| 5141902 | Avatrombopag maleate | 677007-74-8 | 96% |  |
| Avatrombopag maleate is an orally bioavailable, small molecule thrombopoietin recepto | ||||
| 1810251 | AZD-3514 | 1240299-33-5 | >98% |  |
| AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer | ||||
| 1810223 | AZ32 | no | >98% |  |
| AZ32 is an orally bioavailable and blood-brain barrier-penetrating ATM inhibitor with | ||||
| 1810222 | ARS-1620 | 1698055-85-4 | >98% |  |
| ARS-1620 is an atropisomeric selective KRAS-G12C inhibitor with desirable pharmacokin | ||||
| 1810175 | AGL-2263 | 638213-98-6 | >98% |  |
| AGL-2263 is a novel insulin receptor inhibitor. | ||||
| 1810173 | AM211 | 1175526-27-8 | >98% |  |
| AM-211 is a novel and potent antagonist of the prostaglandin D2 receptor type 2. | ||||
| 188281 | Arimoclomol maleate | 289893-26-1 | 98% |  |
| Arimoclomol, also known as BRX-220, is potentially useful for the treatment of Nieman | ||||